Q Fever Market

Market Overview The Global Q Fever Market is projected to increase from USD 441.31 Million in 2025 to USD 598.53 Million by 2031, expanding at a CAGR of 5.21%. This market covers the creation and distribution of diagnostic assays, antibiotic treatments, and preventive vaccines designed to manage infections caused by the bacterium Coxiella burnetii. Growth is largely fueled by strict government requirements for livestock screening and the reinforcement of "One Health" strategies that emphasize the surveillance of zoonotic diseases. Furthermore, elevated occupational safety regulations in high-risk industries, such as meat processing and veterinary medicine, are forcing employers to implement routine prophylaxis and testing protocols, ensuring a consistent demand for molecular and serological diagnostic tools. However, the market faces a major hurdle due to the clinical underdiagnosis of the condition, as its vague symptoms often resemble influenza, resulting in misidentification and delayed medical treatment. This diagnostic uncertainty hides the true disease burden and restricts the potential patient population for therapeutics. According to the "European Food Safety Authority," in "2024," there were 805 confirmed human cases of Q fever reported in the European Union for 2023, marking an 11.5% rise from the prior year. This data underscores the ongoing gap between disease prevalence and detection that hinders market scalability. Market Driver The rising global prevalence of zoonotic Q fever infections is fundamentally altering the market landscape by necessitating stronger surveillance frameworks and rapid diagnostic deployment. Because the pathogen Coxiella burnetii shows resilience in environmental reservoirs, public health agencies are increasing monitoring efforts to prevent outbreaks that harm livestock economies and human health. This increase in identified cases reflects both expanding endemic zones and improved detection capabilities within agricultural sectors. For example, according to the Q-GAPS Consortium in July 2025, the "Q fever outbreak in Slovakia" report confirmed a significant resurgence with 11 human hospitalizations in the Prievidza district after decades of dormancy. Additionally, the Australian Government Department of Health and Aged Care reported in October 2025, in the "National Notifiable Diseases Surveillance System" report, that 951 Q fever notifications were recorded between October 2024 and October 2025, a figure significantly higher than the five-year rolling average. A parallel driver is the growing investment in next-generation vaccine research and development, motivated by the limitations of current prophylaxis which often requires difficult pre-screening to avoid hypersensitivity. The market is shifting toward synthetic and subunit vaccine technologies designed to provide immunity without severe reactogenicity, thereby expanding the potential for mass immunization programs for livestock and humans. Government entities and financial stakeholders are increasingly supporting these initiatives to protect agricultural supply chains from economic losses linked to reproductive failures in herds. This trend is highlighted by recent funding; according to Sheep Central in February 2025, in the article "Q Fever vaccine subsidy and research funding needed," the New South Wales Health Department granted AUD 200,000 to the Australian Rickettsial Reference Laboratory to speed up the development of a new human Q fever vaccine. Such funding is crucial for moving candidates through clinical trials and overcoming the scalability barriers that have historically limited the market. Market Challenge The clinical underdiagnosis of Q fever represents a primary obstacle to market growth by masking the true prevalence of the disease. Since Coxiella burnetii infection frequently presents with non-specific symptoms like fatigue and fever, healthcare providers often mistake the condition for common viral illnesses. This ambiguity results in a failure to order the necessary diagnostic tests, leaving a large portion of the patient population undiagnosed. Consequently, the diagnostic and pharmaceutical sectors face reduced revenue potential because the demand for screening assays and antibiotic therapies is directly dependent on accurate clinical identification. This continuing gap between actual incidence and reported figures limits the addressable market and discourages investment in advanced countermeasures. When cases go unrecorded, the perceived return on investment for new therapeutics decreases. Highlighting this issue, according to the "Australian Department of Health and Aged Care," in "2025," there were 951 notified cases of Q fever reported to the National Notifiable Diseases Surveillance System for the year ending in October. This data indicates that while surveillance is active, the disconnect between symptoms and testing protocols continues to restrict the scalable expansion of the Global Q Fever Market. Market Trends The transition to PCR-based molecular diagnostics is fundamentally transforming the Global Q Fever Market by replacing traditional serological methods with high-sensitivity genomic analysis. This technological shift is driven by the necessity for early-stage infection detection and precise quantification of bacterial loads, which antibody-based tests often fail to identify during the acute phase. The availability of advanced platforms is accelerating this transition, enabling laboratories to detect Coxiella burnetii with unprecedented accuracy across complex sample matrices. Underscoring this advancement, according to Qiagen N.V. in June 2024, in the press release "QIAGEN launches new QIAcuity digital PCR assays for microbial applications," the company introduced 35 new wet-lab tested microbial DNA detection assays, thereby expanding the accessibility of high-precision molecular testing tools suitable for infectious disease research and surveillance. Simultaneously, the standardization of routine bulk tank milk monitoring is emerging as a critical trend in the veterinary sector, providing a scalable solution for herd-level disease management. This approach moves away from individual animal screening towards aggregate sampling of commingled milk, enabling cost-effective identification of shedding prevalence in dairy livestock reservoirs. This method has proven highly effective in revealing the cryptic burden of the disease in endemic agricultural regions. For instance, according to Ceva Animal Health in October 2024, in the "Q Fever News Update Autumn 2024," an analysis of 900 bulk tank milk samples collected since 2020 revealed a cumulative positivity rate of 46%, demonstrating the widespread adoption and diagnostic utility of this bulk screening protocol for maintaining agricultural biosecurity. Key Market Players * Sun Pharmaceutical Industries Ltd. * Abbott Laboratories Inc. * Aurobindo Pharma Limited * Pfizer Inc. * Lupin Limited * Bayer AG * Novartis Pharmaceuticals Corporation * GSK plc * Merck & Co., Inc. * Sanofi SA Report Scope In this report, the Global Q Fever Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Q Fever Market, By Type * Acute Q Fever * Chronic Q Fever # Q Fever Market, By Medication Type * Antibiotics * Antimalerial * Corticosteroids * Others # Q Fever Market, By End-Users * Hospitals * Clinics * Research Institutes # Q Fever Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Q Fever Market. Available Customizations: Global Q Fever Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).